Volume 13, Number 5—May 2007
Dispatch
Chikungunya Virus in US Travelers Returning from India, 2006
Table 1
Sample | IgM ELISA† | IgG ELISA† | PRNT‡ | Virus isolation (Vero cells) | RT-PCR§ | Viremia, PFU/mL¶ | Days from onset of illness to collection | State of US residence | Return date, 2006 |
---|---|---|---|---|---|---|---|---|---|
1 |
17.7 |
3.2 |
640 |
– |
– |
NA |
0 |
NJ |
10/12 |
2 |
1.7 |
1.7 |
<10 |
– |
+ |
104.0 |
1 |
CA |
Before 11/28 |
3 |
1.2 |
1.1 |
ND |
+ |
+ |
104.1 |
1 |
IL |
9/29 |
4 |
1.8 |
NS |
ND |
+ |
+ |
106.8 |
2 |
CA |
Before 9/16 |
5 |
1.2 |
0.76 |
ND |
+ |
+ |
105.1 |
2 |
MA |
9/10 |
6 |
1.8 |
1.6 |
<10 |
+ |
+ |
106.0 |
3 |
PA |
Before 8/20 |
7 |
1.6 |
1.2 |
ND |
+ |
+ |
105.3 |
3 |
CA |
10/2 |
8 |
NS |
1.4 |
ND |
– |
+ |
103.9 |
4 |
WI |
10/9 |
9 |
22.0 |
4.3 |
5,120 |
– |
– |
NA |
4 |
CA |
Before 10/6 |
10 |
1.1 |
0.95 |
<10 |
– |
+ |
104.5 |
6 |
CA |
Before 8/13 |
11 |
7.4 |
0.96 |
40 |
– |
– |
NA |
7 |
CA |
Before 9/23 |
12 |
15.0 |
0.60 |
320 |
– |
– |
NA |
8 |
CT |
Before 7/6 |
13 |
26.2 |
1.2 |
160 |
ND |
– |
NA |
8 |
DC |
Before 10/16 |
14 |
12.9 |
5.8 |
1,80 |
ND |
– |
NA |
10 |
CA |
Before 9/22 |
15 |
38.8 |
2.3 |
2,560 |
ND |
ND |
NA |
19 |
CT |
Before 7/6 |
16 |
12.7 |
1.5 |
640 |
ND |
– |
NA |
20 |
IL |
8/23 |
17 |
16.9 |
4.8 |
640 |
ND |
– |
NA |
30 |
IL |
6/25 |
18 |
8.3 |
3.7 |
640 |
ND |
ND |
NA |
31 |
HI |
Before 8/2 |
19 |
6.6 |
1.5 |
640 |
ND |
– |
NA |
31 |
CA |
Before 8/13 |
20 |
2.6 |
6.8 |
320 |
ND |
– |
NA |
34 |
MD |
Before 3/20 |
21 |
5.0 |
NS |
640 |
ND |
– |
NA |
34 |
IL |
Before 9/22 |
22 |
15.1 |
4.1 |
1,280 |
ND |
– |
NA |
38 |
CA |
Before 10/2 |
23 |
4.3 |
5.9 |
2,560 |
ND |
– |
NA |
42 |
PA |
Before 8/20 |
24 |
5.6 |
NS |
320 |
ND |
– |
NA |
43 |
Unknown |
Unknown |
25 |
3.1 |
3.7 |
640 |
ND |
– |
NA |
44 |
IL |
Before 9/12 |
26 |
26.6 |
13.4 |
5,120 |
ND |
ND |
NA |
48 |
SC |
6/24 |
27 |
30.7 |
6.6 |
5,120 |
ND |
– |
NA |
61 |
CA |
Before 10/26 |
28 |
6.1 |
11.4 |
2,560 |
ND |
– |
NA |
62 |
CT |
Before 10/3 |
29 |
9.4 |
16.0 |
640 |
ND |
– |
NA |
63 |
CA |
8/23 |
30 |
7.5 |
8.4 |
1,280 |
ND |
– |
NA |
71 |
MN |
6/8 |
31 |
5.3 |
5.8 |
640 |
ND |
– |
NA |
71 |
MN |
6/8 |
32 |
3.7 |
16.1 |
320 |
ND |
– |
NA |
75 |
LA |
Before 3/30 |
33 |
9.8 |
10.1 |
2,560 |
ND |
– |
NA |
92 |
IL |
7/9 |
34 |
7.5 |
3.1 |
160 |
ND |
– |
NA |
101 |
PA |
Before 10/13 |
35 | 24.6 | 11.9 | 20,480 | ND | – | NA | Unknown | IL | Before 11/08 |
*IgM, immunoglobulin M; PRNT, plaque reduction neutralization test; RT-PCR, reverse transcription–PCR; NA, not applicable; ND, not done
(sampled depleted); NS, nonspecific reaction in ELISA.
†Values are patient sample optical densities divided by a negative control optical density; values >3 are positive.
‡Values are 90% plaque reduction neutralization titers.
§Real-time, fluorescence-based assay for detecting CHIKV RNA; positive samples had crossing threshold values <37 with both primer sets.
¶Estimated CHIKV PFU/mL by real-time RT-PCR using a standard curve generated with plaque-titrated/calibrated CHIKV standards.
Page created: June 24, 2010
Page updated: June 24, 2010
Page reviewed: June 24, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.